In a phase I/II trial, forty-one NHL patients were administered CD19CAR T cells containing a defined ratio of CD8+ and CD4+ CAR T cells; an objective response rate (ORR) of 84% and a complete response rate (CR) of 47% were observed in those who received CD19CAR T cells in addition to cyclophosphamide and fludarabine conditioning regimen [46]. This evidence concerns the gene CD4 and non-Hodgkin lymphoma.